The IRA has had and will likely continue to have a significant impact on the pharmaceutical industry.
All entries for: Spyre Therapeutics, Inc.
February 19, 2026
Spyre Therapeutics, Inc.
Neutral Outlook
Waltham, MA
51-200 employees
In May 2025, President Trump issued another Executive Order that directed government agencies and officials to identify most-favored nation pricing targets for prescription drugs (and looked to pharmaceutical manufacturers to make significant progress towards delivering target prices to patients); prevent foreign countries from disproportionately shifting the cost of global pharmaceutical research and development to the United States; and facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers to sell their products to patients at the most-favored-nation price.